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Abstract: Background. This study was designed to identify the factors associated with the outcome after standard treatment with surgery and postoperative radiotherapy (RT) for locally advanced salivary gland cancers.
Methods. We conducted a retrospective review of patients with salivary gland cancers registered in the University of Pittsburgh databases from 1990 to 2006.
Results. A total of 74 patients were analyzed. Histologic types included salivary duct carcinoma, 24%; adenoid cystic carcinoma, 23%; and adenocarcinoma, 19%; N2, 39%; N0-1, 58%; and major salivary gland origin, 80%. With a median follow-up of 4.1 years, the 5-year recurrence-free survival (RFS) was 49%, and the 5-year overall survival (OS) was 55%. The 5-year local RFS was 76% and the 5-year distant RFS was 60%. Using Cox-regression analysis, advanced N classification (N2) was the only significant predictor of both RFS and OS.
Conclusion. The long-term survival of patients with highrisk, locally advanced salivary gland cancers is unsatisfactory. Advanced nodal disease is strongly associated with patient outcome and should be considered as a stratification factor in future trials in locally advanced salivary gland cancers. Salivary gland cancers arise from either the major (parotid, submandibular, or sublingual) or minor salivary glands located within the upper aerodigestive tract. Surgery is the mainstay of treatment; however, the prognosis of patients with salivary gland cancer varies considerably. The clinical behavior of these cancers is dependent upon histology, grade, and stage. 1 There are nearly 40 histologic types of salivary gland tumors, with some being exceedingly rare. Salivary gland cancers are generally classified into low-grade, intermediate, and high-grade categories. The degree of differentiation tends to correlate with the incidence of lymph node metastases, extent of local invasion, and overall survival (OS). [2] [3] [4] [5] [6] [7] Overall, the stage of the disease may be the most critical factor for determining the outcome of patients with salivary gland malignancies. 8 Other pathologic features that may affect prognosis include positive surgical margins, extracapsular extension, bone invasion, or perineural invasion.
Patients with either advanced tumors (stage III or IV) or certain histologies, such as adenoid cystic carcinoma which has a propensity for perineural invasion, are at an increased risk of locoregional recurrence. Retrospective studies have shown the addition of adjuvant radiation therapy (RT) to surgical resection provides superior disease control. [9] [10] [11] [12] In advanced parotid cancers, Spiro et al 13 showed the local recurrence rate after surgical resection is 50% to 60%. 14 Although there are no randomized trials comparing surgery alone to surgery with adjuvant RT, retrospective studies suggest that combined-modality therapy is superior to surgery alone for patients with advanced tumor (T) or nodal (N) classification. [15] [16] [17] [18] [19] [20] The rarity of salivary gland cancer poses challenges in their study and the design of novel therapeutic interventions for this disease. We reviewed our experience with patients with locally advanced salivary gland cancers treated with definitive surgery and postoperative radiation therapy in our center to identify predictors of recurrence-free and OS in a group of homogeneously treated patients. Our analysis may be useful in the design of prospective clinical trials in this clinical setting.
PATIENTS AND METHODS
This was a retrospective review of patients with malignant salivary gland tumors registered with the University of Pittsburgh databases from 1990 to 2006. Our review was approved by the Institutional Review Board and was in compliance with Health Insurance Portability and Accountability Act regulations. Salivary gland cancers were staged according to the TNM staging system of the American Joint Committee on Cancer. Histopathology types were classified using the World Health Organization classification. Our selection criteria included newly diagnosed stage III or IV salivary gland cancer treated by surgical excision with a curative intent without macroscopic residual disease followed by postoperative RT. Patients with early-stage or distant metastatic disease, history of other malignancies (including skin cancers), nonsalivary gland pathology, history of immunosuppression, or previous treatment were excluded.
The OS was measured from the time of surgery to the last follow-up or death, and was estimated using the Kaplan-Meier method. Recurrence-free survival (RFS) was measured from the time of surgery to the date of recurrence, death from any cause, or last follow-up, and was estimated using the Kaplan-Meier method as well. In addition to RFS, which includes any site of disease recurrence, local RFS, and distant RFS were estimated.
To identify prognostic factors that might influence survival, log-rank tests were performed to examine the univariate associations between survival and parameters of interest, which included: age, sex, stage, primary site, histologic type and pathologic features (grade, perineural invasion, extracapsular spread, and positive margins), year of treatment, pathologic stage T and N classifications, and treatment type. Histologic grade risk group categorization is detailed in Table 1 .
A step-down Bonferroni adjustment of p values was used to control for multiple comparisons. 21 Cox proportional hazard regression analysis was used to model OS as a function of age, primary site (parotid and submandibular vs minor, and pathologic N classification; N0-1 vs N2), and RFS as a function of primary site and pathologic N classification. 22 All analyses were performed using SAS version 9.1.3 (Cary, NC).
RESULTS
Between 1990 and 2006, a total of 399 cases with salivary gland cancer of any stage and prior treatment status were identified in our databases. Of these, 74 cases met inclusion criteria. Patient characteristics are displayed in Table 1 . The median age was 59 years (range, 21-90 years). Seventy percent of the patients had a malignancy arising from the parotid gland. The most common histologic types were adenoid cystic carcinoma (23%), salivary duct carcinoma (12%), adenocarcinoma (19%), and mucoepidermoid carcinoma (14%); 62% of patients had lymph node metastasis. Of the patients with available detailed pathological information, 64% had extracapsular spread in at least 1 lymph node, 81% perineural invasion, 51% positive margins (13% with a positive margin only at the facial nerve), and 88% high-risk histology. Of the 37 patients with positive resection margins, 9 had positive margins only at the facial nerve.
The median postoperative RT dose was 60 Gy (range, 45-72 Gy). Fourteen patients (19%) also received adjuvant chemotherapy, 10 of them with concurrent carboplatin per treating physician preference. Twelve of the 14 patients who received concurrent chemoradiotherapy had advanced N classification (N2).
Recurrence-Free and Overall Survival. The median follow-up of alive patients was 4.1 years with 14 of the alive patients being followed for at least 4 years. The median OS was 5.5 years (95% confidence interval [CI], 4.1, 10.3). The 3-and 5-year OS probabilities were 72% (95% CI, 61.9%, 83.2%) and 55% (95% CI, 41.1%, 66.7%), respectively ( Figure 1) .
Thirty-three patients (45%) developed a recurrence of their cancer: 11 (15%) had locoregional recurrences, 19 (26%) had distant recurrences, and 3 (4%) had both locoregional and distant recurrences. The most common sites of distant recurrences were lung (n ¼ 11), bone (n ¼ 6), and liver (n ¼ 3). The median RFS was 4.5 years (95% CI, 3.6, NA) and the probabilities of 3-and 5-year RFS were 64.5% (95% CI, 52.9%, 76.0%) and 48.8% (95% CI, 35.3%, 62.3%; Figure 2 ). Median local and distant RFS have not been reached. The 3-and 5-local RFS were 80.7% (95% CI, 70.2%, 90.5%) and 76.0% (95% CI, 61.2%, 85.5%), respectively. The 3-and 5-distant RFS were 77.3% (95% CI, 67.1%, 87.5%) and 60.2% (95% CI, 45.6%, 74.8%), respectively.
Prognostic Factors. We examined univariate associations between survival and parameters of interest using the log-rank test (Table 1) . Of the prognostic factors considered, age at diagnosis had a significant relationship with OS (p ¼ .01). As age increases, the risk of death increased minimally (hazard ratio [HR] ¼ 1.04). However, age at diagnosis did not affect risk of recurrence (p ¼ 1.00).
Patients with advanced N classification were at a significant risk of disease recurrence and death. The median RFS for patients with N0-1 classification was 7.6 years and for patients with N2 classification was 2 years (p ¼ .004). The median OS for patients with N0-1 and N2 disease was 6.6 years versus 2.8 years, respectively (p ¼ .03; Figure 3) . Also, the primary site (minor vs major salivary glands) was of potential significance for patient outcome. The median RFS for patients with minor salivary gland cancers was not reached and for patients with major salivary gland cancers it was 3.8 years; the median OS was 10.3 and 4.7 years for patients with minor and major salivary gland cancers, respectively. The 3-and 5-year RFS for patients with major salivary gland cancers were 59.2% (95% CI, 45.9%, 72.5%) and 40.3% (95% CI, 25.4%, 55.8%), whereas the 3-and 5-year RFS for patients with minor salivary gland cancers were 93.3% (95% CI, 80.7%, 100%) and 81.7% (95% CI, 57.6%, 100%). The 3-and 5-year OS for patients with major salivary gland cancers were 69.3% (95% CI, 57.0%, 81.5%) and 45.9% (95% CI, 31.4%, 60.5%), whereas the 3-and 5-year OS for patients with minor salivary gland cancers were 85.6% (95% CI, 66.9%, 100%) and 85.6% (95% CI, 66.9%, 100%), respectively. However, the p values for the comparison of outcomes between major and minor salivary gland primary sites were not significant after Bonferroni adjustments were made (Table 1) . Abbreviations: OS, overall survival; RFS, recurrence-free survival; HR, hazard ratio; NR, not reached. *Include acinic cell carcinoma (5), myoepithelial carcinoma (2), polymorphous adenocarcinoma (1), carcinoma (1). Note: High-risk grade group includes the following histologic types: squamous cell carcinoma; salivary duct carcinoma; carcinoma ex pleomorphic adenoma; carcinosarcoma; highgrade adenocarcinoma, not otherwise specified; high-grade mucoepidermoid carcinoma; adenoid cystic carcinoma, and solid.
There was no association between the site of the recurrence and resection margin status. No differences in local RFS could be detected for margin status (unadjusted log-rank p ¼ .296) or histology (unadjusted log-rank p ¼ .360).
We used Cox proportional hazards regression to model OS as a function of age, primary site (major vs minor), and pathologic N classification (N0-1 vs N2). Primary site, age (HR ¼ 1.04; p ¼ .001), and nodal status (HR ¼ 3.11; p ¼ .001) were significant predictors of OS (Table 2) . Modeling RFS as a function of primary site and pathologic N classification (N0-1 vs N2) showed that pathologic N classification was the only significant covariate in the model (HR ¼ 3.05; p ¼ .0021).
DISCUSSION
In this series, we attempted to define a patient population with high-risk locally advanced salivary gland cancers that were homogeneously treated. Most previous reports have examined prognostic factors in more heterogeneous groups of patients with various stages of disease that were treated with surgery with or without postoperative RT. 1, 9, 20, [23] [24] [25] Other reports have focused on certain histologies or primary sites of salivary gland cancers. [9] [10] [11] [17] [18] [19] 26 We selected patients with stage III/IV salivary gland cancer who underwent a potentially curative resection followed by postoperative RT to evaluate the outcome of patients and identify predictors of RFS and OS. Due to our selection criteria (ie, the requirement for administration of postoperative RT), our patients had several high-risk features, including positive margins (51%), extracapsular spread (64%), and perineural invasion (81%). Also, there was a relatively high representation of patients with salivary duct carcinoma histology (24%), which is a particularly aggressive histologic type. Despite standard treatment with curative intent, the 5-year RFS in our patients was only 49%. We found that the single factor associated with both a higher risk of recurrence and death was advanced N classification. Our data also suggested that minor salivary gland location may have a better prognosis; however, this association was marginal and not statistically significant in univariate analysis when corrected for multiple testing. Moreover, our sample size did not allow for an evaluation of outcome by various histological subtypes. Due to the rarity and diversity of salivary gland cancers, interpreting prognostic data is challenging. Prior retrospective reviews have shown that prognosis for patients with salivary gland cancer depends upon histology, grade, and stage. 1, 23 Other tumor characteristics which might affect prognosis include positive surgical margins, extracapsular extension, bone invasion, or perineural invasion. Overall, stage may be the most critical factor. 8 However, the significance of the aforementioned unfavorable prognostic factors when patients are treated with postoperative RT is uncertain.
Retrospective data have shown that postoperative RT in locally advanced salivary gland cancer improves locoregional control. [15] [16] [17] [18] [19] [20] In patients with microscopic disease present at or close to the surgical margin, postoperative RT reduced the incidence of local recurrence. 27 Renehan et al 28 reported a trend toward a survival benefit for patients with high-grade tumors and tumors 4 cm in size treated with postoperative RT. In a series from the Dutch Head and Neck Oncology Cooperative Group, postoperative RT significantly improved 10-year local control compared to surgery alone in patients with T3-4 tumors (84% vs 18%), close resection margins (95% vs 55%), bone invasion (86% vs 54%), and perineural invasion (88% vs 60%). 16 In our review, 9 of 37 patients with positive surgical margins were only positive at the facial nerve; however, the clinical impact of positive margins at the facial nerve only versus a nonresected positive margin is beyond the scope of this report. Nevertheless, margin status did not predict RFS in our patients who were all treated with postoperative RT.
A matched-pair analysis from Memorial SloanKettering showed that the local control for stage III and IV disease in patients who received combined-modality therapy (ie, surgery followed by RT) versus patients who underwent surgery alone at 5 years was 51% versus 17%, respectively. 15 A study from the University of Florida reported that the 10-year locoregional control in T4 tumors was 66% with surgery followed by radiation and 24% with RT alone. 29 A retrospective review from Johns Hopkins University in patients with cancer of the major salivary glands who underwent surgery with or without radiation therapy showed that the local recurrence rates were significantly lower in patients who received adjuvant RT (4% vs 26%). 30 Five-year survival rates for patients treated with and without radiation therapy were 75% versus 59%, respectively, whereas the use of adjuvant RT was a significant predictor of survival on multivariate analysis. In a large series by Terhaard et al 16 from the Dutch Head and Neck Oncology Cooperative Group, 498 patients with malignant salivary gland cancers were treated with (n ¼ 386) or without (n ¼ 112) adjuvant RT, and followed for a median of 76 months. Despite a greater frequency of poor prognostic features in the radiation therapy group, (more positive neck nodes, more locally-advanced tumors) actuarial rates of local control were significantly higher with radiation therapy at both 5 and 10 years (94% vs 84%, and 91% vs 76%, respectively). Similar to our study, Teo et al, 24 who reviewed data on 50 patients with nondisseminated salivary gland carcinomas of whom 42 were treated with surgical resection followed by postoperative RT, noted that N classification was the main prognostic factor for overall and RFS.
In our series, patients with N2 disease had a median OS of only 2.8 years despite treatment with postoperative RT. It is possible that concurrent chemoradiotherapy will be beneficial in these patients as it has been demonstrated in patients with locally advanced squamous cell carcinoma of the head and neck. However, there are no large prospective trials on the role of adjuvant concurrent chemotherapy RT for resected salivary gland cancers. In another retrospective study by Hocwald et al, 20 patients who received adjuvant chemotherapy and radiation had a longer disease-free survival. We did not detect a benefit in a small number of our patients (17%) who received radiosensitizing chemotherapy concurrent with RT. However, a small sample size and selection bias could have accounted for the lack of a detectable benefit with concurrent chemoradiotherapy, as our patients treated with chemoradiotherapy had an advanced N classification.
Our study has a number of limitations. A detailed analysis by histologic type was not possible due to the sample size. Also, our median follow-up was approximately 4 years, which may be relatively short for certain salivary gland cancers; however, given the aggressive nature of the selected salivary gland cancers, many events occurred in the first 5 years of follow-up.
The long-term outcome of patients with highrisk, locally advanced salivary gland cancer remains unsatisfactory. The intent of this study was to identify patients who are at a greatest risk for recurrence of cancer after standard treatment. We noted that patients with advanced N classification have poorer survival. Pretreatment parameters, including sex, positive margins, perineural invasion, extracapsular, grade or histology, which have been relevant in other studies, did not influence outcome, possibly due to patient selection. In order to improve treatment outcomes, we suggest the investigation of the addition of novel agents to postoperative RT in prospective clinical trials. Our observations can be potentially used in the design of prospective studies in salivary gland cancers by ensuring proper selection of patients and stratification in randomized clinical trials.
